The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.
Clinically stable with a diagnosis of schizophrenia confirmed by the mini international neuropsychiatric interview [MINI] for psychotic disorders
The participant must be on a stable dose of only one atypical antipyschotic medication
Must be receiving outpatient treatment for schizophrenia from a psychiatric provider at the time of screening
At the Baseline visit, must have a presence of permitted background antipsychotic medication based on blood samples drawn at the screening visit
Has one or more of the current or prior (lifetime) diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) diagnoses (based on the MINI for psychotic disorders): intellectual disability, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, psychotic disorder not otherwise specified (NOS), substance-induced psychotic disorder, bipolar disorder, major depressive disorder (recurrent or current episode)
Has a history of moderate-to-severe substance use disorder, including alcohol use disorder, according to DSM-5 criteria within 6 months before screening except for nicotine or caffeine (based on the MINI and clinical judgment)
Current cannabis (marijuana, pot, grass, hash, etcetera) use exceeds 3 to 5 times over the past 30 days as measured by items from the national survey on drug use and health (NSDUH) questionnaire
Has a history in the past 6 months of a peptic ulcer, or lifetime history of upper gastrointestinal bleeding, or known untreated helicobacter pylori infection, or has a diagnosis of zollinger-ellison syndrome (ZES)
Parallel
Aticaprant
DrugParticipants will receive aticaprant during the double blind (DB) treatment phase.
Placebo
DrugParticipants will receive placebo during the DB treatment phase.
Screen Pass Rate
Screening pass rate of participants will be reported.
Exploratory Assessment-Specific Completion Rate
Assessment specific completion rate of participants will be reported.
Total Assessment Completion Rate
Study Completion Rate
Click on the lead sponsor to view all of their trials.
